Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
7.08
12.29
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Pre-Tax Income
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Pre-Tax Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shenzhen Hepalink Pharmaceutical Group Co Ltd
SZSE:002399
|
Pre-Tax Income
-¥222.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Pre-Tax Income
¥3.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
|
Pre-Tax Income
¥3.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Pre-Tax Income
¥5.9B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
2%
|
CAGR 10-Years
13%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Pre-Tax Income
¥5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
5%
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Pre-Tax Income
-¥769m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shenzhen Hepalink Pharmaceutical Group Co Ltd
Glance View
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. stands as a prominent player in the global pharmaceutical landscape, carving its niche with a remarkable story of specialization and expansion. Founded in 1998, the company first made its mark as a leading producer of heparin sodium, a critical anticoagulant used worldwide to prevent and treat blood clots. Operating from Shenzhen, China, Hepalink has meticulously built an integrated production chain that spans from the procurement of raw materials to the sale of finished pharmaceutical products. The company sources raw heparin from porcine intestines, which it then processes into pharmaceutical-grade heparin and low molecular weight heparins (LMWHs), leveraging its proprietary purification and synthesis technologies. This robust vertical integration not only ensures quality control but also bolsters its competitive positioning in global markets, where it serves hospitals, pharmaceutical companies, and research institutions. Beyond its heparin-centric foundation, Hepalink has strategically expanded its portfolio through a series of calculated ventures and acquisitions aimed at broadening its business model and revenue streams. Over the years, it has diversified into contract development and manufacturing services (CDMO), biotechnology innovations, and the production of other complementary pharmaceutical products. Its acquisition strategies, such as the purchase of U.S.-based Cytovance Biologics, have been pivotal in gaining an international footprint and enriching its expertise in biologics. By investing in research and development, Hepalink continues to explore biologically derived treatments, aiming to lead in therapeutic areas like oncology and cardiology. This diversification effort not only mitigates the risks inherent in relying heavily on a single product line but also positions Hepalink as an agile and innovative player, ready to navigate the ever-evolving pharmaceutical industry landscape.
See Also
What is Shenzhen Hepalink Pharmaceutical Group Co Ltd's Pre-Tax Income?
Pre-Tax Income
-222.3m
CNY
Based on the financial report for Sep 30, 2024, Shenzhen Hepalink Pharmaceutical Group Co Ltd's Pre-Tax Income amounts to -222.3m CNY.
You don't have any saved screeners yet
